azn

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca plc (NYSE: AZN) released a bevy of news today, including Q2 results, as well as study results for two drugs. AZN price has plummeted 15%.Following the loss of exclusivity for Crestor and Seroquel XR AstraZeneca had expected losses in the..